Defensins purified from human granulocytes bind c1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV- 1

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The transmembrane glycoprotein gp41 of HIV-1 contains a C1q binding domain (HIVenv 583-610) and activates the human complement system through the classical pathway. Based on structural and functional similarities between human defensins (human neutrophil peptide, HNP 1-3) and synthetic peptides representing the env 583-610 region of HIV-1, we found it interesting to investigate the C1 q binding and complement activating ability of human defensins. Human defensins were purified and characterized by size exclusion chromatography, ultrafiltration, gel electrophoresis and HPLC. The complement activating ability of the purified peptides was assessed in a solid-phase immunoassay. Defensins, fixed to an ELISA plate, were able to bind the C1q subcomponent of the first complement component (C1), triggering the classical pathway of complement activation which led to CAb binding to the plate. Reduction and subsequent alkylation of disulfide bridges of defensins greatly decreased the C1q binding ability but complement activation (C4b binding) remained high. Further acetylation of the reduced defensin peptide resulted in a molecule which bound very little or no C1q but still activated the complement cascade. These phenomena indicate that defensins interact with the complement system via C1q-dependent and C1q-independent mechanisms, and extend the number of functional similarities between defensins and gp41 of HIV-1 to include C1q binding and complement activation.

Original languageEnglish
Pages (from-to)809-816
Number of pages8
JournalMolecular Immunology
Volume34
Issue number11
DOIs
Publication statusPublished - Aug 1997

Fingerprint

HIV Envelope Protein gp41
Classical Complement Pathway
Defensins
Granulocytes
HIV-1
Glycoproteins
Complement Activation
Peptides
Complement C4b
Complement C1
Ultrafiltration
Alkylation
Acetylation
Immunoassay
Disulfides
Gel Chromatography
Electrophoresis
Gels
Enzyme-Linked Immunosorbent Assay
High Pressure Liquid Chromatography

Keywords

  • Clq binding
  • Complement activation
  • Defensins
  • gp41

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

@article{a6a5c6a1dda448fc8283288987a9ba3f,
title = "Defensins purified from human granulocytes bind c1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV- 1",
abstract = "The transmembrane glycoprotein gp41 of HIV-1 contains a C1q binding domain (HIVenv 583-610) and activates the human complement system through the classical pathway. Based on structural and functional similarities between human defensins (human neutrophil peptide, HNP 1-3) and synthetic peptides representing the env 583-610 region of HIV-1, we found it interesting to investigate the C1 q binding and complement activating ability of human defensins. Human defensins were purified and characterized by size exclusion chromatography, ultrafiltration, gel electrophoresis and HPLC. The complement activating ability of the purified peptides was assessed in a solid-phase immunoassay. Defensins, fixed to an ELISA plate, were able to bind the C1q subcomponent of the first complement component (C1), triggering the classical pathway of complement activation which led to CAb binding to the plate. Reduction and subsequent alkylation of disulfide bridges of defensins greatly decreased the C1q binding ability but complement activation (C4b binding) remained high. Further acetylation of the reduced defensin peptide resulted in a molecule which bound very little or no C1q but still activated the complement cascade. These phenomena indicate that defensins interact with the complement system via C1q-dependent and C1q-independent mechanisms, and extend the number of functional similarities between defensins and gp41 of HIV-1 to include C1q binding and complement activation.",
keywords = "Clq binding, Complement activation, Defensins, gp41",
author = "Z. Proh{\'a}szka and K. N{\'e}met and P. Csermely and F. Hudecz and G. Mező and G. F{\"u}st",
year = "1997",
month = "8",
doi = "10.1016/S0161-5890(97)00097-7",
language = "English",
volume = "34",
pages = "809--816",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Defensins purified from human granulocytes bind c1q and activate the classical complement pathway like the transmembrane glycoprotein gp41 of HIV- 1

AU - Prohászka, Z.

AU - Német, K.

AU - Csermely, P.

AU - Hudecz, F.

AU - Mező, G.

AU - Füst, G.

PY - 1997/8

Y1 - 1997/8

N2 - The transmembrane glycoprotein gp41 of HIV-1 contains a C1q binding domain (HIVenv 583-610) and activates the human complement system through the classical pathway. Based on structural and functional similarities between human defensins (human neutrophil peptide, HNP 1-3) and synthetic peptides representing the env 583-610 region of HIV-1, we found it interesting to investigate the C1 q binding and complement activating ability of human defensins. Human defensins were purified and characterized by size exclusion chromatography, ultrafiltration, gel electrophoresis and HPLC. The complement activating ability of the purified peptides was assessed in a solid-phase immunoassay. Defensins, fixed to an ELISA plate, were able to bind the C1q subcomponent of the first complement component (C1), triggering the classical pathway of complement activation which led to CAb binding to the plate. Reduction and subsequent alkylation of disulfide bridges of defensins greatly decreased the C1q binding ability but complement activation (C4b binding) remained high. Further acetylation of the reduced defensin peptide resulted in a molecule which bound very little or no C1q but still activated the complement cascade. These phenomena indicate that defensins interact with the complement system via C1q-dependent and C1q-independent mechanisms, and extend the number of functional similarities between defensins and gp41 of HIV-1 to include C1q binding and complement activation.

AB - The transmembrane glycoprotein gp41 of HIV-1 contains a C1q binding domain (HIVenv 583-610) and activates the human complement system through the classical pathway. Based on structural and functional similarities between human defensins (human neutrophil peptide, HNP 1-3) and synthetic peptides representing the env 583-610 region of HIV-1, we found it interesting to investigate the C1 q binding and complement activating ability of human defensins. Human defensins were purified and characterized by size exclusion chromatography, ultrafiltration, gel electrophoresis and HPLC. The complement activating ability of the purified peptides was assessed in a solid-phase immunoassay. Defensins, fixed to an ELISA plate, were able to bind the C1q subcomponent of the first complement component (C1), triggering the classical pathway of complement activation which led to CAb binding to the plate. Reduction and subsequent alkylation of disulfide bridges of defensins greatly decreased the C1q binding ability but complement activation (C4b binding) remained high. Further acetylation of the reduced defensin peptide resulted in a molecule which bound very little or no C1q but still activated the complement cascade. These phenomena indicate that defensins interact with the complement system via C1q-dependent and C1q-independent mechanisms, and extend the number of functional similarities between defensins and gp41 of HIV-1 to include C1q binding and complement activation.

KW - Clq binding

KW - Complement activation

KW - Defensins

KW - gp41

UR - http://www.scopus.com/inward/record.url?scp=0344222176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344222176&partnerID=8YFLogxK

U2 - 10.1016/S0161-5890(97)00097-7

DO - 10.1016/S0161-5890(97)00097-7

M3 - Article

C2 - 9444979

AN - SCOPUS:0344222176

VL - 34

SP - 809

EP - 816

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 11

ER -